Conference 2021 Pre-Recorded Video


Project title

Study of clinico-pathological profile of colorectal cancer in North of Morocco.


Authors and Affiliations

Mouade El Bali1, Mohamed Mesmoudi1,2, Mohcine Bennani Mechita1

1. Biomedical Genomics and Oncogenetics Research team (ERGBO), Faculty of Sciences and Techniques of Tangier, Abdelmalek Essaâdi University, Morocco
2. Ahmad Bin Zayed Al Nahyan oncology center of Tangier, Morocco




Colorectal cancer (CRC) represents the third most common type of cancer and the second cause of death by cancer worldwide. Its incidence is estimated at 9.6/10000 habitants with 900000 deaths in 2018 according to the world health organization. In Morocco, colorectal cancer represents the third type of cancer in term of frequency (6.7% of all cancers) with an incidence of 7.8/100000 habitants. In North of Morocco, no study has been carried out to assess the clinico-pathologic profile of CRC. The current retrospective study aimed to describe clinico-pathologic characteristics of CRC patients who visited Ahmad Bin Zayed Al Nahyan regional oncology center of Tangier, between 2017 and 2019.


Data were retrieved from patients medical records and analyzed using SPSS software version 23.


142 colorectal patients were enrolled in this study. The males/females ratio was 1.5:1. The average age of our patients was 58±12.86, with 29.6% of cases aged between 60 and 69 years. More than one third (37%) of our patients were metastatic at diagnosis. The rectum site was diagnosed in 44% of our patients, left and right colon represented 40% and 16% of cases, respectively. Adenocarcinomas lieberkünien was the most common histopathological type with 81% of cases, and the majority of adenocarcinomas (50.1%) were moderately differentiated.


Our findings are generally in accordance with western literature except the higher frequency of rectum cases and the increased rate of metastatic stages, which may reflect the problem of late diagnosis in our population. Larger multicenter studies are warranted to confirm our data.